An antagonist of the MT2 receptor
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

4-P-PDOT

Item No. 17411

Technical Information
Formal Name
N-(1,2,3,4-tetrahydro-4-phenyl-2-naphthalenyl)-propanamide
CAS Number
134865-74-0
Synonyms
  • AH 024
  • cis-4-phenyl-2-Propionamidotetralin
Molecular Formula
C19H21NO
Formula Weight
Purity
≥98%
Formulation
A crystalline solid
DMF: 30 mg/mlDMF:PBS (pH 7.2) (1:9): 0.1 mg/mlDMSO: 15 mg/mlEthanol: 5 mg/ml
λmax
262 nm
SMILES
O=C(CC)NC1CC(C2=CC=CC=C2)C3=C(C=CC=C3)C1
InChi Code
InChI=1S/C19H21NO/c1-2-19(21)20-16-12-15-10-6-7-11-17(15)18(13-16)14-8-4-3-5-9-14/h3-11,16,18H,2,12-13H2,1H3,(H,20,21)
InChi Key
RCYLUNPFECYGDW-UHFFFAOYSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

    Add

    Add

    Add

    Add

    Product Description

    4-P-PDOT is an antagonist of the melatonin 2 (MT2) receptor (pKi = 8.37) that displays 60-fold selectivity for MT2 over MT1.1,2 4-P-PDOT is used in cells, explants, and animals to elucidate the role of MT2 in melatonin-mediated signaling.3,4

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Browning, C., Beresford, I., Fraser, N., et alPharmacological characterization of human recombinant melatonin mt1 and MT2 receptors. Br. J. Pharmacol. 129(5), 877-886 (2000).

    2. Dubocovich, M.L., Masana, M.I., Iacob, S., et alMelatonin receptor antagonists that differentiate between the human Mel1a and Mel1b recombinant subtypes are used to assess the pharmacological profile of the rabbit retina ML1 presynaptic heteroreceptor. Naunyn-Schmiedeberg's Arch. Pharmacol. 355(3), 365-375 (1997).

    3. Juszczak, M., Wolak, M., Bojanowska, E., et alThe role of melatonin membrane receptors in melatonin-dependent oxytocin secretion from the rat hypothalamo-neurohypophysial system - an in vitro and in vivo approach. Endokrynol. Pol. 67(5), 507-514 (2016).

    4. Shin, E.-J., Chung, Y.-H., TLe, H.-L.T., et alMelatonin attenuates memory impairment induced by Klotho gene deficiency via interactive signaling between MT2 receptor, ERK, and Nrf2-related antioxidant potential. Int. J. Neuropsychopharmacol. 18(6), (2015).